News
RARE
40.02
-7.28%
-3.14
Positive Outlook on Ultragenyx Pharmaceuticals Driven by Strong Financials and Promising Pipeline
TipRanks · 56m ago
Ultragenyx Pharma Is Maintained at Overweight by Piper Sandler
Dow Jones · 1d ago
Ultragenyx Pharma Price Target Raised to $140.00/Share From $135.00 by Piper Sandler
Dow Jones · 1d ago
Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $140
Benzinga · 1d ago
Ultragenyx Pharma Price Target Maintained With a $48.00/Share by Wedbush
Dow Jones · 1d ago
Wedbush Reiterates Neutral on Ultragenyx Pharmaceutical, Maintains $48 Price Target
Benzinga · 1d ago
Ultragenyx Pharmaceutical (RARE) Receives a Hold from Wedbush
TipRanks · 1d ago
Evercore ISI Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanks · 1d ago
Ultragenyx price target raised to $140 from $135 at Piper Sandler
TipRanks · 1d ago
TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)
TipRanks · 1d ago
Truist Financial Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks · 1d ago
Optimistic Outlook for Ultragenyx: Buy Rating Affirmed Amid Promising Product Developments and Strong Revenue Projections
TipRanks · 1d ago
Weekly Report: what happened at RARE last week (0106-0110)?
Weekly Report · 1d ago
U.S. RESEARCH ROUNDUP- Constellation Brands, Merck, WD-40
Reuters · 2d ago
ULTRAGENYX PHARMACEUTICAL INC <RARE.O>: PIPER SANDLER RAISES TARGET PRICE TO $140 FROM $135
Reuters · 2d ago
Strong Buy Recommendation for Ultragenyx Pharmaceutical Based on Robust Performance and Promising Clinical Pipeline
TipRanks · 2d ago
Ultragenyx Pharmaceutical: Strong Revenue Forecasts and Pipeline Advancements Justify Buy Rating
TipRanks · 2d ago
ULTRAGENYX PHARMACEUTICAL INC - PRELIMINARY 2024 TOTAL REVENUE OF $555 MLN TO $560 MLN, EXCEEDING TOP END OF GUIDANCE
Reuters · 2d ago
ULTRAGENYX PHARMACEUTICAL INC - 2025 REVENUE GUIDANCE $640M-$670M
Reuters · 2d ago
Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones
Barchart · 2d ago
More
Webull provides a variety of real-time RARE stock news. You can receive the latest news about Ultragenyx Pharm through multiple platforms. This information may help you make smarter investment decisions.
About RARE
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.